<DOC>
	<DOCNO>NCT01063075</DOCNO>
	<brief_summary>The primary purpose study help answer follow research question ( ) : - To see body absorbs , process , get rid cetuximab drug take combination carboplatin [ pharmacokinetic ( PK ) analysis ] - To see drug interaction occur cetuximab carboplatin .</brief_summary>
	<brief_title>A Study Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>The participant histologically cytologically confirm advanced solid tumor resistant standard therapy standard therapy . The participant measurable nonmeasurable disease accord RECIST 1.0 guideline . The participant life expectancy great 3 month . The participant Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . The participant adequate hematologic function define absolute neutrophil count great equal 1500/microliter ( μL ) , hemoglobin great equal 9 grams/deciliter ( g/dL ) , platelet count great equal 100,000/μL . The participant adequate hepatic function define total bilirubin less equal 2 x upper limit normal ( ULN ) , aspartate transaminase ( AST , SGOT ) alanine transaminase ( ALT , SGPT ) less equal 3 x ULN ( less equal 5 x ULN presence know liver metastasis ) . The participant adequate renal function define serum creatinine less equal 1.5 x institutional ULN creatinine clearance great equal 60 mL/min participant creatinine level ULN . The participant ability understand , willingness sign , write informed consent document . If participant receive prior therapy platinum , time first treatment study drug last platinum exposure &gt; 28 day . The participant symptomatic brain leptomeningeal metastasis . The participant recover adverse event due agent administer 4 week earlier . Neurotoxicity , present , must improve Grade le 2 per National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) v 3.0 . The participant receive investigational agent ( ) . The participant receive concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiation therapy ( RT ) , chemoembolization , target therapy . Participants receive palliative radiation therapy bony metastasis prior first dose study medication eligible . The participant receiving therapy immunosuppressive agent . The participant know drug alcohol abuse . The participant uncontrolled hypertension define systolic blood pressure great equal 180 millimeter mercury ( mm Hg ) diastolic blood pressure great equal 130 mm Hg . The participant history allergic reaction attribute compound chemical biologic composition similar cetuximab carboplatin . The participant medical psychological condition would permit participant complete study sign inform consent . The participant clinically relevant coronary artery disease history myocardial infarction last 12 month high risk uncontrolled arrhythmia uncontrolled cardiac insufficiency . The participant , female , pregnant ( confirm serum urine betahuman chorionic gonadotropin [ βHCG ] pregnancy test ) breastfeed The participant know positive test result human immunodeficiency virus . The participant active infection ( require I.V antibiotic ) , include tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cancer Head</keyword>
	<keyword>Cancer Head Neck</keyword>
	<keyword>Cancer Neck</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Head Cancer</keyword>
	<keyword>Head Neoplasms</keyword>
	<keyword>Head , Neck Neoplasms</keyword>
	<keyword>Neck Cancer</keyword>
	<keyword>Neck Neoplasms</keyword>
	<keyword>Solid Neoplasm</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Sarcoma</keyword>
</DOC>